SCHEMBL3600937

SCHEMBL3600937

Cc1nn(C)c(Sc2cccc(O)c2)c1CO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.52
POLB P06746 1/20 0.48
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
HSD17B2 P37059 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34
GCGR P47871 1/20 0.34
RET P07949 1/20 0.33
KIF5B P33176 1/20 0.33
KDR P35968 1/20 0.33
MAPT P10636 2/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3612443 0.83 HSD17B2 (0.40) SMN1; SMN2POLBMEN1KMT2ACYP1A2
SCHEMBL3617878 0.77 HSD17B2 (0.36) SMN1; SMN2POLBMEN1KMT2ACYP1A2
SCHEMBL3609583 0.77 MAPT (0.43) SMN1; SMN2POLBMEN1KMT2ACYP1A2
SCHEMBL31281467 0.66 CA12 (0.58) SMN1; SMN2CYP2C9HSD17B2TDP1LMNA
SCHEMBL2239504 0.66 CA12 (0.58) SMN1; SMN2CYP2C9HSD17B2TDP1LMNA
SCHEMBL3607355 0.66 PTPN11 (0.35) SMN1; SMN2POLBMEN1KMT2ACYP1A2
SCHEMBL3609034 0.66 SMN1; SMN2 (0.36) SMN1; SMN2POLBRAB9A
SCHEMBL3614801 0.65 NPSR1 (0.37) SMN1; SMN2MEN1KMT2ACYP1A2CYP2C9
SCHEMBL19209446 0.64 SMN1; SMN2 (0.51) SMN1; SMN2POLBMEN1KMT2ACYP1A2
SCHEMBL30620468 0.62 ACHE (0.50) MEN1KMT2ACYP1A2CYP2C19HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R SMN1; SMN2 4515/4885POLB 3604/4885MEN1 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.